Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

References for PMC Articles for PubMed (Select 21467166)

1.

Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome.

Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EM, Tybulewicz VL, Hart IR, Hodivala-Dilke KM.

Nature. 2010 Jun 10;465(7299):813-7. doi: 10.1038/nature09106. Erratum in: Nature. 2010 Jul 15;466(7304):398.

2.

PCR prescreen for genotyping the Ts65Dn mouse model of Down syndrome.

Lorenzi H, Duvall N, Cherry SM, Reeves RH, Roper RJ.

Biotechniques. 2010 Jan;48(1):35-8. No abstract available.

3.

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.

Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, Ryeom S.

Nature. 2009 Jun 25;459(7250):1126-30. doi: 10.1038/nature08062. Epub 2009 May 20.

4.

Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis.

Wei G, Srinivasan R, Cantemir-Stone CZ, Sharma SM, Santhanam R, Weinstein M, Muthusamy N, Man AK, Oshima RG, Leone G, Ostrowski MC.

Blood. 2009 Jul 30;114(5):1123-30. doi: 10.1182/blood-2009-03-211391. Epub 2009 May 1.

5.

Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner.

Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quiñones OA, Reilly KM.

Mamm Genome. 2009 Apr;20(4):214-23. doi: 10.1007/s00335-009-9179-4. Epub 2009 Apr 4.

6.

A neural crest deficit in Down syndrome mice is associated with deficient mitotic response to Sonic hedgehog.

Roper RJ, VanHorn JF, Cain CC, Reeves RH.

Mech Dev. 2009 Mar-Apr;126(3-4):212-9. doi: 10.1016/j.mod.2008.11.002. Epub 2008 Nov 21.

7.

Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth.

Ryeom S, Baek KH, Rioth MJ, Lynch RC, Zaslavsky A, Birsner A, Yoon SS, McKeon F.

Cancer Cell. 2008 May;13(5):420-31. doi: 10.1016/j.ccr.2008.02.018.

8.

Trisomy represses Apc(Min)-mediated tumours in mouse models of Down's syndrome.

Sussan TE, Yang A, Li F, Ostrowski MC, Reeves RH.

Nature. 2008 Jan 3;451(7174):73-5. doi: 10.1038/nature06446.

PMID:
18172498
9.

The power of comparative and developmental studies for mouse models of Down syndrome.

Moore CS, Roper RJ.

Mamm Genome. 2007 Jul;18(6-7):431-43. Epub 2007 Jul 26. Review.

10.

Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis.

Minami T, Horiuchi K, Miura M, Abid MR, Takabe W, Noguchi N, Kohro T, Ge X, Aburatani H, Hamakubo T, Kodama T, Aird WC.

J Biol Chem. 2004 Nov 26;279(48):50537-54. Epub 2004 Sep 23.

11.

Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):13008-13. Epub 2004 Aug 19.

12.

Comparative pathology of nerve sheath tumors in mouse models and humans.

Stemmer-Rachamimov AO, Louis DN, Nielsen GP, Antonescu CR, Borowsky AD, Bronson RT, Burns DK, Cervera P, McLaughlin ME, Reifenberger G, Schmale MC, MacCollin M, Chao RC, Cichowski K, Kalamarides M, Messerli SM, McClatchey AI, Niwa-Kawakita M, Ratner N, Reilly KM, Zhu Y, Giovannini M.

Cancer Res. 2004 May 15;64(10):3718-24.

13.

Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis.

Wolvetang EJ, Bradfield OM, Hatzistavrou T, Crack PJ, Busciglio J, Kola I, Hertzog PJ.

Neurobiol Dis. 2003 Dec;14(3):349-56.

PMID:
14678752
14.
15.

ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway.

Wolvetang EJ, Wilson TJ, Sanij E, Busciglio J, Hatzistavrou T, Seth A, Hertzog PJ, Kola I.

Hum Mol Genet. 2003 Feb 1;12(3):247-55.

16.

Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study.

Yang Q, Rasmussen SA, Friedman JM.

Lancet. 2002 Mar 23;359(9311):1019-25.

PMID:
11937181
17.

Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes.

Ergün S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S, Kilic E, Chalajour F, Fiedler W, Lauke H, Lamszus K, Hammerer P, Weil J, Herbst H, Folkman J.

Angiogenesis. 2001;4(3):193-206.

PMID:
11911017
18.

High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours.

Zorick TS, Mustacchi Z, Bando SY, Zatz M, Moreira-Filho CA, Olsen B, Passos-Bueno MR.

Eur J Hum Genet. 2001 Nov;9(11):811-4.

19.

Angiogenesis-dependent diseases.

Folkman J.

Semin Oncol. 2001 Dec;28(6):536-42. Review.

PMID:
11740806
20.

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.

Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T.

Nat Genet. 2000 Sep;26(1):109-13.

PMID:
10973261
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk